INNOVATRIX CAPITAL

Our mission is to derisk Clinical Trials in order to encourage vital global drug development. 

Our solutions are designed to provide downside risk protection for clinical trials by paying out in the event of failure.

Despite $55bn spent annually worldwide on Clinical Trials this is not enough to meet the demand for new drugs. 

Attracting sufficient investment for much needed drug development is a long standing challenge as it is high risk, expensive and low return.

Innovatrix was established to change this by acting as a bridge between the Life Sciences and Risk Capital markets.

Our suite of solutions offer downside risk protection through Parametric (model driven) or traditional Indemnity based insurance products for any registered Clinical Trial irrespective of Therapeutic Area, Geography or Phase.